Garden State Microbiome
Garden State Microbiome
Podcast Description
The Garden State Microbiome explores New Jersey’s rich microbiology scene across academia, industry, and government. Meet the microbiologists driving discoveries at Rutgers, Princeton, Center for Discovery & Innovation, Rowan, Wm Paterson, Montclair State, Seton Hall, NJIT, and biotech giants like Merck, Pfizer, Bristol-Myers, and J&J. In New Jersey, microbiology connects healthcare, environment, and biotech in powerful ways. Join us in discovering why it’s a small state with a big microbiology—brought to you by the Theobald Smith Society, the NJ branch of the American Society for Microbiology
Podcast Insights
Content Themes
The show explores various themes within microbiology, including marine microbiology, environmental impacts, and healthcare innovations, with specific episodes detailing topics like microbial life in coastal systems, the role of microbes in biogeochemical cycles, and the impact of climate change on microbiomes.
The Garden State Microbiome explores New Jersey’s rich microbiology scene across academia, industry, and government. Meet the microbiologists driving discoveries at Rutgers, Princeton, Center for Discovery & Innovation, Rowan, Wm Paterson, Montclair State, Seton Hall, NJIT, and biotech giants like Merck, Pfizer, Bristol-Myers, and J&J. In New Jersey, microbiology connects healthcare, environment, and biotech in powerful ways. Join us in discovering why it’s a small state with a big microbiology—brought to you by the Theobald Smith Society, the NJ branch of the American Society for Microbiology
In this episode of The Garden State Microbiome, we’re joined by Dr. Lynn Silver, a microbiologist whose career spans the evolution of modern antibiotic discovery—from early bench science to leading antibacterial teams at Merck & Co., and later, advising biotech firms across the globe.
Dr. Silver shares lessons from decades spent developing antibacterial compounds, emphasizing that single-target drugs often fail the test of time—they’re too easy for bacteria to outwit. Instead, the future lies in multi-target molecules and strategic antibiotic combinations. Her insights explain why some drugs succeed while others collapse under resistance pressure.
She also reflects candidly on why she left Merck. As managerial responsibilities grew and the problem-solving joy of scientific inquiry diminished, the tradeoff no longer felt worth it. But consulting has been a different story. For over 20 years, Dr. Silver has helped startups and research organizations ask better questions and find smarter answers about antibiotics—not always lucrative, but deeply fulfilling and intellectually rich.
This episode offers both a history lesson and a personal one: about staying engaged, contributing meaningfully, and finding joy in lifelong learning—even after leaving the corporate lab bench.
Guest: Dr. Lynn Silver
Former Senior Principal Scientist, Merck & Co. Consultant in antibacterial discovery and development Global expert in antibiotic resistance
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.